Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
6 min read
Socazolimab Biologics Sequence Review Report 2026: PD-L1 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Socazolimab, an antibody targeting PD-L1.
6 min read
Bebtelovimab Biologics Sequence Review Report 2026: SARS-CoV-2 Spike RBD Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bebtelovimab, an antibody targeting SARS-CoV-2 Spike RBD.
6 min read
Stapokibart Biologics Sequence Review Report 2026: IL-4Ralpha Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Stapokibart, an antibody targeting IL-4Ralpha.
6 min read
Enlonstobart Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enlonstobart, an antibody targeting PD-1.
Latest Hotspot
6 min read
Tislelizumab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tislelizumab, an antibody targeting PD-1.
6 min read
Bermekimab Biologics Sequence Review Report 2026: IL-1α Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bermekimab, an antibody targeting IL-1α.
6 min read
Canakinumab Biologics Sequence Review Report 2026: IL-1β Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Canakinumab, an antibody targeting IL-1β.
6 min read
Romilkimab Biologics Sequence Review Report 2026: IL-4/IL-13 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Romilkimab, a bispecific antibody targeting IL-4/IL-13.
6 min read
Setrusumab Biologics Sequence Review Report 2026: Sclerostin Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Setrusumab, an antibody targeting Sclerostin.
6 min read
Burosumab Biologics Sequence Review Report 2026: FGF23 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Burosumab, an antibody targeting FGF23.
6 min read
Denosumab Biologics Sequence Review Report 2026: RANKL Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Denosumab, an antibody targeting RANKL.
6 min read
Romosozumab Biologics Sequence Review Report 2026: Sclerostin Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Romosozumab, an antibody targeting Sclerostin.